T-VEC treatment shows promise for treating advanced stage liver tumours
Phase 1 data supports the use of image-guided therapy for difficult to treat cancer...
List view / Grid view
Phase 1 data supports the use of image-guided therapy for difficult to treat cancer...
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
Researchers have developed a biodegradable hydrogel scaffold system to release chemotherapeutic and immunotherapeutic drugs at the tumour site...
The FDA has approved Imfinzi for the treatment of patients with stage III non-small cell lung cancer whose tumours are not able to be surgically removed and whose cancer has not progressed after treatment...
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
A drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant...
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer...
This application note describes a sensitive, fast and accurate LC/MS/MS quantitation method utilising a QSight™ 110 Triple Quadrupole Mass Spectrometer for the simultaneous analysis of the immunosuppressant drugs tacrolimus, sirolimus and cyclosporine A in serum, using everolimus as an internal standard...
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
Scientists have uncovered a key factor in the development of immunotherapy resistance in the case of cutaneous melanoma. This could potentially lead to future improvements in cancer therapy.
The European Commission (EC) has approved Sandoz’ (a Novartis division) Erelzi (biosimilar etanercept) for use in Europe, to treat inflammatory diseases...
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...